Avoro Capital Advisors Reduces $37M in MoonLake Immunotherapeutics ($MLTX)

Avoro Capital Advisors has completely exited its position in MLTX, selling all 2 million shares it previously held. This move was disclosed in the latest 13F filing with the SEC, reflecting transactions as of the reporting period.

What Changed in Avoro Capital Advisors' MLTX Position

Avoro Capital Advisors sold its entire stake of 2 million shares in MLTX, resulting in a 100% reduction of its holdings. The firm no longer holds any shares in the company, marking a full exit from its previous position.

Other Institutional Activity in MLTX

Several other institutional investors have also adjusted their positions in MLTX. BVF Inc/IL reduced its holdings by 3.75 million shares, ending with about 16 million shares valued at approximately $298.3 million. Meanwhile, Deep Track Capital, LP increased its stake by nearly 1.8 million shares, resulting in a total of about 6.4 million shares worth $119.5 million. Cormorant Asset Management, LP added 125,000 shares, bringing its total to approximately 4.48 million shares valued at $83.5 million. Janus Henderson Group PLC significantly boosted its position by adding over 1.35 million shares, now holding around 3.45 million shares valued at $64.3 million. D. E. Shaw & Co., Inc. slightly trimmed its holdings by 90,106 shares, finishing with about 2.39 million shares worth $44.6 million.

MLTX Stock Snapshot

Shares of MLTX are trading at approximately $18.69. The stock's performance is closely monitored by both institutional investors and analysts, who have various outlooks on its potential.

Insider Buying and Selling at MoonLake Immunotherapeutics

Several insider transactions were reported at MLTX. Matthias Bodenstedt, the Chief Financial Officer, sold shares on multiple occasions under a Rule 10b5-1 trading plan. On May 11, 2026, he sold 13,653 shares at an average price of $20.02. Earlier, on April 14, 2026, he sold 2,426 shares at $19.56. Additionally, Jorge Santos Da Silva, the CEO, sold 51,873 shares at $18.23 on April 13, 2026, and 98,127 shares at $18.41 on April 10, 2026.

Analysts Set New Price Targets

On May 12, 2026, Needham maintained its 'buy' rating on MLTX with a price target of $30. HC Wainwright & Co. also maintained a 'buy' rating, setting a target of $45 on May 11, 2026. Earlier in March, Wolfe Research upgraded the stock to a 'buy' with a target of $24, and Rothschild & Co followed with a 'buy' rating and a target of $40. The consensus remains positive with a general 'buy' recommendation.

Bottom Line

Avoro Capital Advisors' complete exit from MLTX highlights some shifting views among institutional investors. The stock remains a point of interest, trading around $18.69, with analysts generally maintaining optimistic price targets. Investors will continue to watch how these changes play out, keeping an eye on future filings for updated positions.